公司的曼海欣为我国首个脑膜炎球菌四价结合疫苗产品，其上市缩小了我国在该领域与发达国家的差 距，填补了我国在该领域缺乏高端疫苗的空白，为我国6周岁及以下儿童流脑疾病的预防提供了更优解 决方案。曼海欣凭借其创新优势，展现出强劲的市场表现力，实现了市场占有率的不断攀升。 康希诺生物(06185)发布公告，公司已获得国家药监局出具的《药品补充申请批准通知书》，根据该通 知书，国家药监局已批准公司的ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)("MCV4"，商品名 称：曼海欣)的适用人群年龄范围由"3月龄到3周岁(47月龄)儿童"扩大至"3月龄到6周岁(83月龄)儿童"的 补充申请。 ...

智通财经APP讯，康希诺生物(06185)发布公告，公司已获得国家药监局出具的《药品补充申请批准通知 书》，根据该通知书，国家药监局已批准公司的ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体) ("MCV4"，商品名称：曼海欣®)的适用人群年龄范围由"3月龄到3周岁(47月龄)儿童"扩大至"3月龄到6 周岁(83月龄)儿童"的补充申请。 公司的曼海欣®为我国首个脑膜炎球菌四价结合疫苗产品，其上市缩小了我国在该领域与发达国家的差 距，填补了我国在该领域缺乏高端疫苗的空白，为我国6周岁及以下儿童流脑疾病的预防提供了更优解 决方案。曼海欣®凭借其创新优势，展现出强劲的市场表现力，实现了市场占有率的不断攀升。 ...

格隆汇2月24日丨康希诺生物(06185.HK)宣布，公司已获得中国国家药监局出具的《药品补充申请批准 通知书》，根据该通知书，国家药监局已批准公司的ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载 体)(「MCV4」，商品名称：曼海欣®)的适用人群年龄范围由「3月龄到3周岁(47月龄)儿童」扩大至「3 月龄到6周岁(83月龄)儿童」的补充申请。 公司的曼海欣®为我国首个脑膜炎球菌四价结合疫苗产品，其上市缩小了我国在该领域与发达国家的差 距，填补了我国在该领域缺乏高端疫苗的空白，为我国6周岁及以下儿童流脑疾病的预防提供了更优解 决方案。曼海欣®凭借其创新优势，展现出强劲的市场表现力，实现了市场占有率的不断攀升。 ...

公司的曼海欣®为我国首个脑膜炎球菌四价结合疫苗产品，其上市缩小了我国在该领域与发达国家的差 距，填补了我国在该领域缺乏高端疫苗的空白，为我国6周岁及以下儿童流脑疾病的预防提供了更优解 决方案。曼海欣®凭借其创新优势，展现出强劲的市场表现力，实现了市场占有率的不断攀升。 格隆汇2月24日丨康希诺生物(06185.HK)宣布，公司已获得中国国家药监局出具的《药品补充申请批准 通知书》，根据该通知书，国家药监局已批准公司的ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载 体)(「MCV4」，商品名称：曼海欣®)的适用人群年龄范围由「3月龄到3周岁(47月龄)儿童」扩大至「3 月龄到6周岁(83月龄)儿童」的补充申请。 ...

证券代码：688185 证券简称：康希诺 公告编号：2026-003 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，康希诺生物股份公司（以下简称"公司"）收到国家药品监督管理局 下发的《药品补充申请批准通知书》，公司产品 ACYW135 群脑膜炎球菌多糖结 合疫苗（CRM197 载体）（以下简称"MCV4"）适用人群年龄范围由"3 月龄 ~3 周岁（47 月龄）儿童"扩大至"3 月龄~6 周岁（83 月龄）儿童"。现将相关 情况公告如下： 一、产品及补充申请情况 药品名称：ACYW135 群脑膜炎球菌多糖结合疫苗（CRM197 载体） 商品名称：曼海欣® 剂型：注射剂 注册分类：预防用生物制品 准文号：国药准字 S20210054 康希诺生物股份公司 关于ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体） 获得补充申请批准通知书的公告 上市许可持有人：康希诺生物股份公司 主要审批结论：根据《中华人民共和国药品管理法》《中华人民共和国疫苗 管理法》及有关规定，经审查，本品此次申请事项符合药品注册的有关要求，批 ...

曼海欣®为我国首个脑膜炎球菌四价结合疫苗产品，于2021年12月获批上市。其上市缩小了我国在该领 域与发达国家的差距，填补了我国在该领域缺乏高端疫苗的空白，为我国6周岁及以下儿童流脑疾病的 预防提供了更优解决方案。曼海欣®凭借其创新优势，展现出强劲的市场表现力，实现了市场占有率的 不断攀升。 格隆汇2月24日丨康希诺(688185.SH)公布，公司收到国家药品监督管理局下发的《药品补充申请批准通 知书》，公司产品ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）（以下简称"MCV4"）适用人 群年龄范围由"3月龄~3周岁（47月龄）儿童"扩大至"3月龄~6周岁（83月龄）儿童"。 ...

每经AI快讯，2月24日，康希诺(688185.SH)公告称，公司产品ACYW135群脑膜炎球菌多糖结合疫苗 （CRM197载体）适用人群年龄范围由"3月龄~3周岁（47月龄）儿童"扩大至"3月龄~6周岁（83月龄） 儿童"。该疫苗为我国首个脑膜炎球菌四价结合疫苗产品，其适用人群年龄范围的扩大预计将对公司业 绩产生积极影响。 ...

曼海欣®为我国首个脑膜炎球菌四价结合疫苗产品，于2021年12月获批上市。其上市缩小了我国在该领 域与发达国家的差距，填补了我国在该领域缺乏高端疫苗的空白，为我国6周岁及以下儿童流脑疾病的 预防提供了更优解决方案。曼海欣®凭借其创新优势，展现出强劲的市场表现力，实现了市场占有率的 不断攀升。 格隆汇2月24日丨康希诺(688185.SH)公布，公司收到国家药品监督管理局下发的《药品补充申请批准通 知书》，公司产品ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）（以下简称"MCV4"）适用人 群年龄范围由"3月龄~3周岁（47月龄）儿童"扩大至"3月龄~6周岁（83月龄）儿童"。 ...

Core Viewpoint - The article highlights the significant decline in the stock prices of high-priced new shares in the A-share market, with a staggering 70% of the top ten highest-priced new stocks falling below their issuance prices, leading to substantial losses for investors [1][4]. Group 1: Stock Performance - Seven out of the ten highest-priced new stocks have dropped below their issuance prices, with a breakage rate of 70% [1][4]. - The stock with the most severe decline, 康希诺 (688185), plummeted from a peak of 797.2 yuan to 63.9 yuan, representing a drop of over 93% [2][3]. - Other high-priced stocks like 禾迈股份 (688032) and 万润新能 have also seen significant declines, with their prices falling below their issuance prices, resulting in substantial losses for investors [3][4]. Group 2: Reasons for Decline - The decline in high-priced new stocks can be attributed to three main factors: excessively high issuance prices, a decline in industry popularity, and poor performance post-listing [4][5]. - Many of these stocks had issuance price-to-earnings ratios far exceeding industry averages, leading to overvaluation at the time of listing [4]. - The fading popularity of sectors such as vaccines and solar energy has resulted in companies struggling to maintain high valuations due to lack of performance support [4][5]. Group 3: Investor Sentiment and Market Trends - Investors have expressed frustration, noting that the previous trend of guaranteed profits from new stock subscriptions has shifted to a more lottery-like experience, where risks are significantly higher [4][5]. - The article emphasizes the importance of avoiding blind speculation and highlights the need for investors to focus on companies with solid fundamentals and reasonable valuations [5][7]. - The collective decline of high-priced new stocks serves as a warning to investors to avoid blindly chasing high prices and to adopt a more rational investment approach [7].

Core Viewpoint - The article discusses the significant decline in the stock prices of ten high-issue-price stocks in the A-share market, with seven of them falling below their issue prices, highlighting the risks associated with high valuations and market sentiment shifts [1][22]. Group 1: Stock Performance - Among the ten stocks, only Stone Technology, Naxin Micro, and BeiGene remain above their issue prices as of mid-February 2026 [6][8]. - The maximum decline from issue prices includes: - CanSino down 69.15% - Wanrun New Energy down 58.54% - Huabao New Energy down 54.93% - Yiqiao Shenzhou down 42.22% - Hemai down 32.82% - Foxit Software down 22.17% - Suocheng Technology down 12.83% [10]. - CanSino experienced a dramatic drop of 93% from its peak price of 797.20 yuan to 63.90 yuan [11][19]. Group 2: Company Backgrounds - Hemai, the highest issue price stock at 557.80 yuan, faced a significant decline after reaching a peak of 1877.43 yuan [12]. - Wanrun New Energy, listed at 299.88 yuan, never reached its issue price after its first day of trading [15]. - Yiqiao Shenzhou, with an issue price of 292.92 yuan, peaked at 353.83 yuan before falling to 73.38 yuan [16]. - CanSino, a COVID-19 vaccine stock, was listed at 209.71 yuan and peaked at 797.20 yuan before its decline [17]. Group 3: Market Conditions and Trends - The high issue prices were driven by market enthusiasm for sectors like hard technology, new energy, and biomedicine during the registration reform period from 2020 to 2023 [5][4]. - The overall market sentiment has shifted, leading to a decline in these stocks as the initial excitement waned [22]. - The article notes that the current new stock market shows a stark contrast, with a recent increase in participation and initial gains, but also warns of accumulating risks [24][26]. Group 4: Investment Implications - The high issue prices and P/E ratios of these stocks are no longer guarantees of company strength, but rather potential warning signs of investment risk [28]. - The article emphasizes that the era of easy profits from new stock subscriptions has ended, requiring more thorough research and disciplined investment strategies [27].